Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 71610-939

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 71610-939). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0939 89)

Label for Sacubitril and Valsartan 49 mg/51 mg film-coated tablets. The package contains 720 tablets and is manufactured by MSP Pharmaceuticals Inc., distributed by Aphena Pharma Solutions - Tennessee, LLC. The label includes storage instructions, a barcode, NDC number 71610-939-89, and regulatory information.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Figure-1 (Sacubitril Valsartan Figure 1)

A horizontal dot plot chart showing the geometric mean ratio and 90% confidence interval of various coadministered drugs relative to a reference. The chart compares changes in AUC (solid circles) and Cmax (open circles) for drugs including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil.*

FDA Label Image

Figure-2 (Sacubitril Valsartan Figure 2)

A chart displaying the geometric mean ratio and 90% confidence intervals comparing AUC and Cmax values of LBQ657 and Valsartan across various population descriptions including renal and hepatic impairment levels, age, gender, and racial groups. The chart uses a log scale to show changes relative to reference values for pharmacokinetic parameters.*

FDA Label Image

Sacubitril-valsartan-figure-3.jpg (Sacubitril Valsartan Figure 3)

Three Kaplan-Meier curves from the PARADIGM-HF study comparing Sacubitril and Valsartan versus Enalapril. Figure A shows time to first occurrence of cardiovascular death or heart failure hospitalizations. Figure B depicts time to occurrence of cardiovascular death. Figure C presents time to first occurrence of heart failure hospitalizations. Each graph includes the number at risk over time and hazard ratios with confidence intervals.*

FDA Label Image

Structure (Sacubitril Valsartan Structure)

Chemical structure diagram of the active ingredients Sacubitril and Valsartan, showing their molecular configurations with atoms and bonds clearly illustrated.*

FDA Label Image

Sacubitril-valsartanl-figure-4.jpg (Sacubitril Valsartanl Figure 4)

A forest plot chart comparing hazard ratios with 95% confidence intervals for Sacubitril and Valsartan versus Enalapril across various patient subgroups, including age, gender, weight, race, region, NYHA class, kidney function, diabetes status, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, heart failure history, and more. The horizontal axis ranges from 0.25 to 4, indicating relative outcomes where values less than 1 favor Sacubitril and Valsartan and values greater than 1 favor Enalapril. The left side contains subgroup labels and numerical data on percentage of total population and treatment outcomes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.